Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Change in Acquisitions & Divestments (2023 - 2025)

Summit Therapeutics (SMMT) has disclosed Change in Acquisitions & Divestments for 3 consecutive years, with $150.8 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Change in Acquisitions & Divestments rose 115.45% year-over-year to $150.8 million, compared with a TTM value of $311.3 million through Dec 2025, down 36.44%, and an annual FY2025 reading of $311.3 million, down 36.44% over the prior year.
  • Change in Acquisitions & Divestments was $150.8 million for Q2 2025 at Summit Therapeutics, down from $160.5 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $233.0 million in Q4 2024 and bottomed at $38.2 million in Q2 2023.
  • Average Change in Acquisitions & Divestments over 3 years is $112.1 million, with a median of $109.4 million recorded in 2023.
  • Peak annual rise in Change in Acquisitions & Divestments hit 284.66% in 2024, while the deepest fall reached 32.37% in 2024.
  • Year by year, Change in Acquisitions & Divestments stood at $60.6 million in 2023, then skyrocketed by 284.66% to $233.0 million in 2024, then plummeted by 35.27% to $150.8 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for SMMT at $150.8 million in Q2 2025, $160.5 million in Q1 2025, and $233.0 million in Q4 2024.